1
Clinical Trials associated with iPD-1-Claudin18.2-CAR-T(The Affiliated Hospital of Qingdao University)Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing Trial
The goal of this clinical trial is to assessing the safety and tolerability of XKDCT086 cells against recurrent or refractory solid tumors with Claudin18.2 positivity.This experiment proposes to enroll 9-18 patients, the experimental drug is a chimeric antigen receptor T cell preparation targeting Claudin18.2.
100 Clinical Results associated with iPD-1-Claudin18.2-CAR-T(The Affiliated Hospital of Qingdao University)
100 Translational Medicine associated with iPD-1-Claudin18.2-CAR-T(The Affiliated Hospital of Qingdao University)
100 Patents (Medical) associated with iPD-1-Claudin18.2-CAR-T(The Affiliated Hospital of Qingdao University)
100 Deals associated with iPD-1-Claudin18.2-CAR-T(The Affiliated Hospital of Qingdao University)